Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Why it matters: Novo has struggled to stay competitive with Eli Lilly LLY in developing the next generation of obesity drugs that could improve on Lillys Zepbound, with disappointing data for phase 2 drug monlunabant in September and phase 3 GLP-1 and amylin combination cagrisema in December
UK product information notes that thyroid C-cell tumours have been observed in rodent studies, though the relevance to humans remains uncertain
Reported values are the mean values of each respective category
Gabriel, S
Filomeni, G., Rotilio, G
US$ 24.84
US$ 20.23
US$ 29.95
US$ 28.57
